Suppr超能文献

甲状腺相关眼病的临床特征和临床病程:3620 例中国病例的系列病例。

Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases.

机构信息

Department of Ophthalmology, West China Hospital of Sichuan University, No. 37 Guoxue Xiang, Wuhou District, Chengdu, Sichuan Province, 610041, China.

出版信息

Eye (Lond). 2021 Aug;35(8):2294-2301. doi: 10.1038/s41433-020-01246-7. Epub 2020 Nov 2.

Abstract

OBJECTIVES

To determine the clinical features and course of thyroid-associated ophthalmopathy (TAO) in a large sample of Chinese patients.

DESIGN AND METHODS

We retrospectively identified a cohort of consecutive patients diagnosed with TAO at the West China Hospital from October 1, 2009 to October 1, 2019. We analysed clinical data from 3620 patients, including demographic data, clinical manifestations, ophthalmology examinations, and prognosis.

RESULTS

TAO most frequently occurred with hyperthyroidism, with most patients developing TAO after thyroid disease (TD). The TAO phenotype was asymmetric in 375 (50.7%) euthyroid patients, 25 (27.8%) hypothyroid patients, and 314 (12.1%) hyperthyroid patients (p < 0.0001). The most frequent symptom was lid lag and the most commonly involved extraocular muscle was the inferior rectus. Severity assessment (NOSPECS score) and clinical activity assessment (Clinical Activity Scores, CAS) differed significantly between male and female patients (P < 0.000). The majority (88.8%) of patients had clinically inactive TAO, and only 3.2% of cases were sight-threatening. Regarding the clinical process, 75.5% of patients had an active phase time less than 12 months and 2.1% showed complete remission.

CONCLUSIONS

TAO most commonly develops in females and is closely related to hyperthyroidism. Euthyroid TAO often has an asymmetric clinical phenotype. CAS combined with magnetic resonance imaging can improve the detection of TAO. NOSPECS scores should be slightly refined regarding the criteria for corneal involvement. Clinical management of TAO should be individualized according to CAS or NOSPECS assessments and a multidisciplinary approach is paramount. A minority of patients showed complete remission.

摘要

目的

在大量中国患者中确定甲状腺相关眼病(TAO)的临床特征和病程。

方法

我们回顾性地确定了 2009 年 10 月 1 日至 2019 年 10 月 1 日期间在华西医院诊断为 TAO 的连续患者队列。我们分析了 3620 例患者的临床数据,包括人口统计学数据、临床表现、眼科检查和预后。

结果

TAO 最常与甲状腺功能亢进症相关,大多数患者在甲状腺疾病(TD)后发生 TAO。375 例(50.7%)甲状腺功能正常患者、25 例(27.8%)甲状腺功能减退患者和 314 例(12.1%)甲状腺功能亢进患者的 TAO 表型为不对称(p<0.0001)。最常见的症状是眼睑迟滞,最常受累的眼外肌是下直肌。严重程度评估(NOSPECS 评分)和临床活动评估(临床活动评分,CAS)在男性和女性患者之间差异显著(P<0.000)。大多数(88.8%)患者的 TAO 为临床非活动期,仅有 3.2%的病例为视力威胁性。关于临床过程,75.5%的患者活动期时间小于 12 个月,2.1%的患者完全缓解。

结论

TAO 最常见于女性,与甲状腺功能亢进症密切相关。甲状腺功能正常的 TAO 常表现为不对称的临床表型。CAS 结合磁共振成像可以提高 TAO 的检出率。NOSPECS 评分关于角膜受累的标准应略作修正。根据 CAS 或 NOSPECS 评估进行个体化的 TAO 临床管理,多学科方法至关重要。少数患者完全缓解。

相似文献

1
Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases.
Eye (Lond). 2021 Aug;35(8):2294-2301. doi: 10.1038/s41433-020-01246-7. Epub 2020 Nov 2.
2
[Clinical Analysis of 2 170 Cases of Thyroid-Associated Ophthalmopathy Involving Extraocular Muscles].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 May;52(3):510-515. doi: 10.12182/20210560507.
3
Clinical phenotypes of euthyroid, hyperthyroid, and hypothyroid thyroid-associated ophthalmopathy.
Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):1995-2002. doi: 10.1007/s00417-023-05998-2. Epub 2023 Feb 20.
4
[The value of DCE-MRI in assessing the course of thyroid associated ophthalmopathy].
Zhonghua Yan Ke Za Zhi. 2017 Jun 11;53(6):430-435. doi: 10.3760/cma.j.issn.0412-4081.2017.06.007.
5
Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients.
Eye (Lond). 2012 Sep;26(9):1263-9. doi: 10.1038/eye.2012.132. Epub 2012 Jun 29.
6
Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy.
Thyroid. 2015 Aug;25(8):942-8. doi: 10.1089/thy.2015.0031. Epub 2015 Jun 4.
9

引用本文的文献

1
Pediatric graves' orbitopathy: a case series of 136 Chinese patients.
Int Ophthalmol. 2025 Sep 1;45(1):367. doi: 10.1007/s10792-025-03583-6.
2
Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions.
Front Immunol. 2025 Jul 25;16:1647602. doi: 10.3389/fimmu.2025.1647602. eCollection 2025.
3
Extraocular muscle index as a novel indicator of inflammatory condition in graves' ophthalmopathy patients.
Front Endocrinol (Lausanne). 2025 May 29;16:1594828. doi: 10.3389/fendo.2025.1594828. eCollection 2025.
4
Asymmetry Upper Eyelid Retraction of Thyroid Eye Disease: Change of Lateral Flare Sign With the Natural Course of Untreated Disease.
Scientifica (Cairo). 2025 May 23;2025:1855515. doi: 10.1155/sci5/1855515. eCollection 2025.
5
Combining orbital intensity modulated radiation therapy with periorbital triamcinolone acetonide injection for Graves' orbitopathy.
Int J Ophthalmol. 2025 May 18;18(5):904-911. doi: 10.18240/ijo.2025.05.17. eCollection 2025.
6
Optimal timing for cataract surgery in patients with thyroid-associated ophthalmopathy.
Int J Ophthalmol. 2025 Apr 18;18(4):606-614. doi: 10.18240/ijo.2025.04.06. eCollection 2025.
9
10
TikTok as a potential patient educational tool for thyroid-associated ophthalmopathy: A cross-sectional study.
Digit Health. 2024 Dec 12;10:20552076241304594. doi: 10.1177/20552076241304594. eCollection 2024 Jan-Dec.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验